Move to topTop
September 23, 2019

LAKEWOOD, Colo. USA - 23 September 2019 -Terumo BCT's new USD $100,000 Therapeutic Plasma Exchange (TPE) Innovation Award will help clinical investigators expand the field of data for certain types of autoimmune conditions, known as IgG4-mediated diseases.

TPE is as an established therapy for many diseases, according to the American Society for Apheresis (ASFA), but the understanding of how it works is still emerging. As a result, some insurance providers and government programs will not cover this type of care -- leaving some patients without potentially beneficial treatments.

"The first step in providing innovative therapies is generating data that helps healthcare providers demonstrate how procedures can help improve health outcomes for their patients," said Regis Leonard, Vice President, Therapeutic Systems, Terumo BCT. "This new grant will support the important work of investigators who are working to improve the lives of patients."

TPE takes place on therapeutic apheresis devices, an area of focus for Terumo BCT. The Colorado-based company also works in the fields of blood component and cell therapy technologies. It has customers in about 130 countries.

Impact on Patient Lives

Terumo BCT will judge applications for the TPE Innovation Award based on several factors, including how the applicant plans to address the unmet medical need of understanding and treating IgG4-mediated diseases. The award committee also considers patient impact, feasibility and the likelihood of success. The company will accept applications until 31 October 2019. Terumo BCT's Medical and Clinical Affairs specialists, along with an external committee of experts in the field, will select the winner. Learn more here.

TPE can be performed on Terumo BCT's Spectra Optia® Apheresis System*. The device enables healthcare providers to remove plasma from a patient's blood and replace it with either donated fresh frozen plasma or a mixture containing albumin (a protein found in human blood) to manage a variety of conditions.

TPE is an established therapy for some metabolic, neurologic, hematologic and renal disorders, according to ASFA. For example, ASFA recommends TPE as Category I, or first-line, therapy to manage myasthenia gravis, a chronic autoimmune disease that causes muscle weakness and rapid fatigue. However, many patient groups, including those with IG4-mediated diseases, may not receive TPE as first-line treatment because there is a lack of data demonstrating the efficacy of TPE. Data expansion could potentially allow healthcare providers to provide plasma exchange to their patients with insurance or government reimbursement support.

  • *

    Procedure availability varies by country.

About Terumo BCT

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.